Alpha Cognition Announces Closing of $14.4 Million Public Offering
Vancouver, British Columbia--(Newsfile Corp. - October 1, 2021) - ALPHA COGNITION INC. (TSXV: ACOG) (OTCQB: ACOGF) ("Alpha" or the "Company"), is pleased to announce that it has closed its previously announced public offering of units (the "Units") for aggregate gross proceeds of approximately C$14.4 million, including the exercise of the over-allotment option in full (the "Offering"). The Company issued 9,602,500 Units at a price of C$1.50 per Unit, each Unit consisting of one common...
2021-10-01 9:58 AM EDT
Alpha Cognition Updates Anticipated Closing Date of Public Offering
Vancouver, British Columbia--(Newsfile Corp. - September 29, 2021) - Alpha Cognition Inc. (TSXV: ACOG) ("Alpha" or the "Company"), announces that further to its announcement of the overnight marketed offering through a syndicate of agents led by Raymond James Ltd. and including iA Private Wealth Inc. (collectively, the "Agents") on September 23, 2021, the anticipated closing date of the offering has been extended to October 1, 2021.The TSXV has conditionally approved the offering and the...
2021-09-29 8:30 AM EDT
Alpha Cognition Appoints Lauren D'Angelo as Chief Commercial Officer to Drive Strategic Growth
Vancouver, British Columbia--(Newsfile Corp. - May 4, 2021) - Alpha Cognition Inc. (TSXV: ACOG) ("Alpha Cognition", or the "Company"), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, is pleased to announce the appointment of Lauren D'Angelo to Chief Commercial Officer. In this role, she will ensure the integrated commercial success of the company. Her initial focus will be to...
2021-05-04 9:00 AM EDT
Alpha Cognition to Host Investor Webcast on May 6th, 2021
Vancouver, British Columbia--(Newsfile Corp. - April 30, 2021) - Alpha Cognition Inc. (TSXV: ACOG)("Alpha Cognition", or the "Company"), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, is pleased to announce that it will host a webcast investor presentation on Thursday, May 6th, 2021 at 2:00 PM EDT.During the webcast, Michael McFadden, Chief Executive Officer, will provide a...
2021-04-30 9:00 AM EDT
Alpha Cognition Announces Ms. Colleen Johns as SVP, Product Development Further Strengthening the ALPHA-1062 Drug Commercialization Team
Vancouver, British Columbia--(Newsfile Corp. - April 27, 2021) - . Alpha Cognition Inc. (TSXV: ACOG) ("Alpha Cognition", or the "Company"), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, is pleased to announce that Ms. Colleen Johns has been appointed Senior Vice President, Product Development as part of the Company's plan to further develop the operational and...
2021-04-27 9:00 AM EDT
Alpha Cognition Announces Mr. Michael McFadden as Chief Executive Officer and Realignment of Leadership Team for Next Stage of ALPHA-1062 Drug Development
Vancouver, British Columbia--(Newsfile Corp. - April 12, 2021) - Alpha Cognition Inc. (TSXV: ACOG) ("Alpha Cognition", or the "Company"), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, is pleased to announce that Michael McFadden has been appointed chief executive officer as part of the Company's plan to accelerate growth. Mr. McFadden most recently served as Chief...
2021-04-12 9:00 AM EDT
Alpha Cognition Presenting at the Benzinga Biotech Small Cap Conference
Detroit, Michigan--(Newsfile Corp. - March 23, 2021) - Alpha Cognition Inc. ("ACI"), a biopharmaceutical company focused on neurological disorders, with near term commercialization potential for its Alpha-1062 Alzheimer's drug announced today that Dr. Fred Sancilio, ACI's President will be presenting at the Benzinga Biotech Small Cap Conference on March 24th, 2021 at 10:55 AM ET. The presentation will cover all key aspects of ACI's business including a summary of the de-risked ALPHA-1062...
2021-03-23 9:00 AM EDT
Alpha Cognition Announces Closing of Qualifying Transaction
Vancouver, British Columbia--(Newsfile Corp. - March 22, 2021) - Alpha Cognition Inc. (TSXV: CRYS.P) (formerly Crystal Bridge Enterprises Inc.) (the "Company" or "Alpha Cognition") is pleased to announce the closing of its qualifying transaction (the "Transaction"), as defined in the policies of the TSX Venture Exchange (the "TSXV"), pursuant to which it completed a plan of arrangement (the "Arrangement") with Alpha Cognition Canada Inc. (formerly Alpha Cognition Inc.) ("Alpha Canada")....
2021-03-22 9:03 PM EDT
Crystal Bridge Provides Transaction Update
Vancouver, British Columbia--(Newsfile Corp. - March 8, 2021) - Crystal Bridge Enterprises Inc. (TSXV: CRYS.P) (the "Company") is pleased to provide an update regarding its Qualifying Transaction (the "Transaction") with Alpha Cognition Inc. ("ACI"), as previously announced on July 14, October 28 and December 4, 2020. The Company is pleased to announce that ACI has obtained an interim order of the Supreme Court of British Columbia providing for, among other things, the holding of ACI's...
2021-03-08 8:46 PM EST
Crystal Bridge Announces Receipt by Alpha Cognition of Japanese Patent for Alzheimer Drug Alpha-1062 and Announces Private Placement Updates
Vancouver, British Columbia--(Newsfile Corp. - December 4, 2020) - Crystal Bridge Enterprises Inc. (TSXV: CRYS.P) ("Crystal Bridge", or the "Company") is pleased to announce that Alpha Cognition Inc. ("ACI"), has received confirmation of a patent being granted in Japan for Alpha 1062 drug being developed for use in the treatment of neurodegenerative diseases, including Alzheimer's disease. This patent grant further demonstrates the value of Alpha-1062's patent family globally.The Alzheimer's...
2020-12-04 4:27 PM EST
Crystal Bridge Enters into Arrangement Agreement with Alpha Cognition, Announces up to $13 Million Private Placement
Vancouver, British Columbia--(Newsfile Corp. - October 28, 2020) - Crystal Bridge Enterprises Inc. (TSXV: CRYS) (the "Company") a capital pool company ("CPC") as defined under Policy 2.4 - Capital Pool Companies ("Policy 2.4") of the TSX Venture Exchange (the "Exchange"), is pleased to announce that, further to its news release dated July 14, 2020, the Company and Alpha Cognition Inc. ("ACI"), a private company incorporated under the Business Corporations Act (British Columbia), have entered...
2020-10-28 7:30 AM EDT
Crystal Bridge Enterprises Inc. Reports on the Annual General Meeting
Vancouver, British Columbia--(Newsfile Corp. - July 8, 2020) - CRYSTAL BRIDGE ENTERPRISES INC. (TSXV: CRYS) (the "Company") is pleased to announce the results of its Annual General Meeting ("AGM") held on July 6, 2020. Shareholders voted in favor of all management resolutions proposed in the Management Proxy Circular and as listed below:The number of Directors for the Company was set at Five (5).The five members elected to the Board of Directors include: Rajeev 'Rob' Bakshi, K. Taylor Thoen,...
2020-07-08 6:05 PM EDT